Has Susan Julius received payments from drug or device companies?

Yes. Drug and device makers reported $255,020 in general payments to Susan Julius across 540 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Susan Julius did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Susan Julius come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Susan Julius

Addiction Medicine · Baton Rouge, LANPI 1407921935

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $164,046 of the $255,020 with a category attached, or 64.3%. Gilead accounts for 94.8% of it on its own, with 17 other manufacturers making up the rest. Among addiction medicine clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$255,020in general payments, 2019–2025

Across 540 payments — averaging $472.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Gilead$242K
Eli Lilly$6K
Vanda Pharmaceuticals Inc.$2K
AbbVie$894
Axsome Therapeutics, Inc.$711
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$675
plus $3K from 12 others

What the payments were for

Consulting fees$19,9758%
Speaking & faculty fees$164,04664%
Travel & lodging$57,05922%
Food & beverage$13,8275%
Education$1130%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Gilead	312	$241,874
Eli Lilly	10	$6,402
Vanda Pharmaceuticals Inc.	67	$1,961
AbbVie	30	$894
Axsome Therapeutics, Inc.	13	$711
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	18	$675
Braeburn Inc.	13	$535
Alkermes, Inc.	18	$486
Indivior Inc.	14	$387
Otsuka America Pharmaceutical, Inc.	9	$326
USWM, LLC	11	$177
Johnson & Johnson	2	$153
Alfasigma USA, Inc.	10	$149
E.r. Squibb & Sons, L.L.C.	4	$142
Hikma Pharmaceuticals USA	3	$53
Orexo US, Inc.	3	$45
MDD US Operations, LLC	2	$36
Pfizer	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$255,020 in reported general payments places this provider in the 95th percentile of 28 addiction medicine providers in Louisiana.

See all addiction medicine providers in Louisiana →

Other addiction medicine in Baton Rouge

Brian BensonBaton Rouge$887
Chandra KattaBaton Rouge$435
Louis CataldieBaton Rouge$166
Richard SipesShreveport$56K
Christina JonesSulphur$44K
Kirit PatelShreveport$37K
Alphonse RoyMetairie$23K
Philip IsherwoodShreveport$4K
Indira KailasMarrero$3K
James ChivertonMetairie$2K

See the full list for Louisiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →